US free shipping over $150 · Exact worldwide rate at checkout · Crypto-only checkout guide — Shop now
T
Titan PeptideResearch-grade nasal sprays

Melanotan-2 · cycle length · research use only

How long is a Melanotan-2 cycle? It's the melanocortin compound that actually has one — loading, then maintenance.

Most 'cycle length' questions in the peptide world get a category-error answer: PT-141 has no cycle because it's on-demand, retatrutide has no cycle because it's studied as continuous therapy. Melanotan-2 (MT-2, a synthetic analog of alpha-MSH) is the exception — the published and widely-documented research protocols describe a genuine two-phase cycle. A loading phase runs daily for roughly the first one-to-three weeks and builds cumulative pigmentation; a maintenance phase then drops to roughly twice weekly to hold what the loading phase established. That structure exists because MT-2's melanocortin (MC1R) effect is cumulative — melanin builds over repeated doses rather than resetting between them — so unlike an acute compound, there genuinely is a 'reservoir' to load and then maintain. The original University of Arizona Phase I work (Dorr et al. 1996, PubMed 8637402) established a per-kg dose range and reported pigmentation after only a handful of doses, and later community and vendor protocols formalised the loading-then-maintenance shape. Skin type (Fitzpatrick I–V) is the main variable in how long loading takes. This page reproduces that documented structure as a research reference, explains why MT-2 is cycled when related melanocortin compounds are not, and states the honest limits of the evidence. It is a summary of published pigmentation research, not a human-use protocol, and not medical, cosmetic or dosing advice.

PT-141 nasal spray — $69.99PT-141 vs Melanotan-2

Why MT-2 has a real cycle: the melanocortin effect is cumulative

The reason a loading/maintenance cycle makes sense for MT-2 and not for PT-141 is that MC1R stimulation drives melanin synthesis that accumulates across repeated doses. Each dose adds to a pigmentation 'reservoir' rather than clearing to baseline before the next — so a front-loaded daily phase builds the reservoir, and a lighter maintenance phase offsets its slow decay. An on-demand compound like PT-141 accumulates nothing, which is exactly why it has no cycle. Same melanocortin family, opposite scheduling logic.

Contrast: PT-141 has no cycle →

Phase 1 — loading (roughly weeks 1–3, daily)

Documented protocols describe a daily loading phase intended to build pigmentation to a target depth, commonly starting lower for the first few days and then holding a steady daily amount. The length of loading is driven mainly by Fitzpatrick skin type — fairer skin (types I–II) is reported to need longer loading windows and larger cumulative totals, while darker skin (types III–V) reaches the target faster. Loading is the 'build the reservoir' phase.

Melanotan-2 sourcing notes →

Phase 2 — maintenance (about twice weekly, ongoing)

Once the loading target is reached, documented protocols step down to a much lower frequency — commonly on the order of twice weekly — to offset the slow fade of pigmentation rather than to keep building it. Maintenance is open-ended in the sense that it continues only as long as the pigmentation level is being held; it is not an escalating schedule. This step-down is the defining feature that makes MT-2 a genuine two-phase cycle rather than a flat continuous regimen.

Melanotan-2 adverse-event profile →

The honest limits: community protocol, not a validated clinical cycle

MT-2 has no FDA, TGA or MHRA approval for any indication, and there is no standardised clinical cycle length. The loading/maintenance model is drawn from an early Phase I dose-range study plus decades of self-reported and vendor-published protocols — useful as documentation of what has been described, but not a clinically-validated schedule. Reported figures vary widely by source and by skin type. A research reference should state that plainly rather than present a single 'correct' cycle.

How PT-141 differs mechanistically →

Why the maintenance step-down also limits exposure

Beyond pigmentation, MT-2 is a broad, non-selective melanocortin agonist (it hits MC1R, MC3R, MC4R and MC5R), and its documented adverse-event record includes nausea, blood-pressure changes and — the reason for careful monitoring — darkening and change of moles and nevi. The step-down to maintenance reduces cumulative exposure once the target is met. This is context for why a two-phase cycle is described the way it is, not a safety endorsement; the AE record is covered on the dedicated page.

Full adverse-event record →

Research-use framing and Titan's in-catalog alternative

Everything here summarises published pigmentation research and documented protocols reproduced as a research reference for laboratory and in-vitro modelling — not instructions for human or cosmetic use, and not a claim of efficacy or an optimal schedule in people. Titan does not stock Melanotan-2. For the melanocortin pathway Titan supplies PT-141 (bremelanotide) — the MC4-weighted, FDA-approved metabolite — as a research-use-only nasal spray.

PT-141 nasal spray (in stock) →

The detail, in plain terms

Melanotan-2 'cycle length', separated into structure and caveat.

A plain-terms split between the loading/maintenance structure documented for MT-2 and the honest limits on that data. The two-phase shape is genuine — MT-2 is one of the few melanocortin compounds with a real cycle — but the specific numbers are community/early-study protocol, not a validated clinical schedule. Reproduced as a research reference, not a human-use protocol.

Does MT-2 have a real cycle?
Yes — unusually for a melanocortin compound. The effect is cumulative, so a loading phase builds pigmentation and a maintenance phase holds it.
Loading phase
Documented as daily for roughly weeks 1–3 (often starting lower for the first few days), to build to a target pigmentation depth.
Maintenance phase
Documented as a step-down to roughly twice weekly, ongoing, to offset slow pigmentation fade rather than to keep building.
Main variable
Fitzpatrick skin type — fairer skin (I–II) is reported to need longer loading and larger cumulative totals than darker skin (III–V).
Earliest formal reference
Phase I dose-range work (Dorr et al. 1996, PubMed 8637402) established a per-kg range and reported pigmentation after only a few doses.
Regulatory / validation status
No FDA/TGA/MHRA approval for any indication; no standardised clinical cycle. The protocol is community/early-study, not clinically validated.
Titan catalog note
MT-2 is not stocked. Titan supplies PT-141 (the MC4-weighted FDA-approved metabolite) as a research-use-only nasal spray.

Questions researchers ask

Before you order.

How long is a Melanotan-2 cycle?
Documented protocols describe a two-phase cycle rather than a single length: a loading phase run daily for roughly one-to-three weeks to build pigmentation, followed by an open-ended maintenance phase at a much lower frequency (commonly around twice weekly) to hold it. The loading length depends mainly on Fitzpatrick skin type — fairer skin is reported to need longer loading than darker skin. These figures are drawn from an early Phase I dose-range study plus community and vendor protocols, not a validated clinical schedule. This page is a research reference summarising published pigmentation research, not medical, cosmetic or dosing advice.
Why does Melanotan-2 have a cycle when PT-141 doesn't?
Because the effects accumulate differently. MT-2's MC1R-driven melanin synthesis builds across repeated doses — there is a pigmentation 'reservoir' to load and then maintain — which is exactly what makes a loading/maintenance cycle meaningful. PT-141 is an acute, on-demand melanocortin agonist that clears in hours and accumulates nothing, so it has no cycle, only a per-use frequency cap. They are in the same melanocortin family but have opposite scheduling logic, which is why a 'cycle' fits one and not the other.
What is the difference between the loading and maintenance phase?
The loading phase is the daily 'build' phase — documented as roughly weeks 1–3, intended to raise pigmentation to a target depth. The maintenance phase is the lower-frequency 'hold' phase — documented as a step-down to about twice weekly — intended to offset slow pigmentation fade rather than to keep building. The step-down from daily loading to twice-weekly maintenance is the defining feature that makes MT-2 a genuine two-phase cycle. This is a summary of documented protocols, not a human-use instruction.
Is there a standard clinical Melanotan-2 cycle length?
No. Melanotan-2 has no FDA, TGA, MHRA or other regulatory approval for any indication, and there is no standardised clinical cycle length. The loading/maintenance model comes from an early Phase I dose-range study (Dorr et al. 1996) plus decades of self-reported and vendor-published protocols. Reported numbers vary widely by source and by skin type. An honest research reference documents the described structure while making clear it is not a clinically-validated schedule.
Does Titan sell Melanotan-2?
No. Titan Peptide Lab does not stock Melanotan-2. For the melanocortin pathway Titan supplies PT-141 (bremelanotide) — the MC4-weighted, FDA-approved metabolite of the same lineage — strictly as a research-use-only nasal spray for in-vitro laboratory work, not for human or animal consumption. The MT-2 protocol data on this page is reproduced only as a research reference.

Related reading

Before you check out.